Maarten Vermeer, MD, PhD

In part 2, the debaters map the trial that could settle the question and agree that, for now, individualized care and closer monitoring should guide high-risk early MF.

In the beginning of a two-part debate, two experts agree the evidence to treat poor-prognosis early MF differently from the onset isn’t here yet.